Tolerability and efficacy of classical CMF(cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT). 40th Annual American society of Clinical Oncology Meeting. New Orleans, Louisiana, USA

DW Hiller; HM Earl; JA Dunn; Sarah Bathers; David Spooner; R Grieve; RK Agrawal; CJ Poole

Tolerability and efficacy of classical CMF(cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT). 40th Annual American society of Clinical Oncology Meeting. New Orleans, Louisiana, USA

DW Hiller, HM Earl, JA Dunn, Sarah Bathers, David Spooner, R Grieve, RK Agrawal, CJ Poole

Cancer and Genomic Sciences

Research output: Contribution to journal › Article

Original language	English
Pages (from-to)	p25
Journal	Meetings Proceedings book Abstract no 595
Volume	23
Publication status	Published - 1 Jan 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Hiller, DW., Earl, HM., Dunn, JA., Bathers, S., Spooner, D., Grieve, R., Agrawal, RK., & Poole, CJ. (2004). Tolerability and efficacy of classical CMF(cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT). 40th Annual American society of Clinical Oncology Meeting. New Orleans, Louisiana, USA. Meetings Proceedings book Abstract no 595, 23, p25.

Hiller, DW ; Earl, HM ; Dunn, JA et al. / Tolerability and efficacy of classical CMF(cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT). 40th Annual American society of Clinical Oncology Meeting. New Orleans, Louisiana, USA. In: Meetings Proceedings book Abstract no 595. 2004 ; Vol. 23. pp. p25.

@article{89681b6de8ef4c7fab403ab37f81f877,

title = "Tolerability and efficacy of classical CMF(cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT). 40th Annual American society of Clinical Oncology Meeting. New Orleans, Louisiana, USA",

author = "DW Hiller and HM Earl and JA Dunn and Sarah Bathers and David Spooner and R Grieve and RK Agrawal and CJ Poole",

year = "2004",

month = jan,

day = "1",

language = "English",

volume = "23",

pages = "p25",

journal = "Meetings Proceedings book Abstract no 595",

}

Hiller, DW, Earl, HM, Dunn, JA, Bathers, S, Spooner, D, Grieve, R, Agrawal, RK & Poole, CJ 2004, 'Tolerability and efficacy of classical CMF(cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT). 40th Annual American society of Clinical Oncology Meeting. New Orleans, Louisiana, USA', Meetings Proceedings book Abstract no 595, vol. 23, pp. p25.

Tolerability and efficacy of classical CMF(cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT). 40th Annual American society of Clinical Oncology Meeting. New Orleans, Louisiana, USA. / Hiller, DW; Earl, HM; Dunn, JA et al.
In: Meetings Proceedings book Abstract no 595, Vol. 23, 01.01.2004, p. p25.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Tolerability and efficacy of classical CMF(cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT). 40th Annual American society of Clinical Oncology Meeting. New Orleans, Louisiana, USA

AU - Hiller, DW

AU - Earl, HM

AU - Dunn, JA

AU - Bathers, Sarah

AU - Spooner, David

AU - Grieve, R

AU - Agrawal, RK

AU - Poole, CJ

PY - 2004/1/1

Y1 - 2004/1/1

M3 - Article

VL - 23

SP - p25

JO - Meetings Proceedings book Abstract no 595

JF - Meetings Proceedings book Abstract no 595

ER -

Hiller DW, Earl HM, Dunn JA, Bathers S, Spooner D, Grieve R et al. Tolerability and efficacy of classical CMF(cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT). 40th Annual American society of Clinical Oncology Meeting. New Orleans, Louisiana, USA. Meetings Proceedings book Abstract no 595. 2004 Jan 1;23:p25.